Literature DB >> 16397900

Sodium tungstate decreases the phosphorylation of tau through GSK3 inactivation.

Alberto Gómez-Ramos1, Jorge Domínguez, Delia Zafra, Helena Corominola, Ramon Gomis, Joan J Guinovart, Jesús Avila.   

Abstract

Tungstate treatment increases the phosphorylation of glycogen synthase kinase-3beta (GSK3beta) at serine 9, which triggers its inactivation both in cultured neural cells and in vivo. GSK3 phosphorylation is dependent on the activation of extracellular signal-regulated kinases 1/2 (ERK1/2) induced by tungstate. As a consequence of GSK3 inactivation, the phosphorylation of several GSK3-dependent sites of the microtubule-associated protein tau decreases. Tungstate reduces tau phosphorylation only in primed sequences, namely, those prephosphorylated by other kinases before GSK3beta modification, which are serines 198, 199, or 202 and threonine 231. The phosphorylation at these sites is involved in reduction of the interaction of tau with microtubules that occurs in Alzheimer's disease. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16397900     DOI: 10.1002/jnr.20726

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  6 in total

Review 1.  GSK3beta: role in therapeutic landscape and development of modulators.

Authors:  S Phukan; V S Babu; A Kannoji; R Hariharan; V N Balaji
Journal:  Br J Pharmacol       Date:  2010-03-19       Impact factor: 8.739

2.  Sodium Tungstate for Promoting Mesenchymal Stem Cell Chondrogenesis.

Authors:  Ateka Khader; Lauren S Sherman; Pranela Rameshwar; Treena L Arinzeh
Journal:  Stem Cells Dev       Date:  2016-10-17       Impact factor: 3.272

3.  Anti-obesity sodium tungstate treatment triggers axonal and glial plasticity in hypothalamic feeding centers.

Authors:  Marta Amigó-Correig; Sílvia Barceló-Batllori; Guadalupe Soria; Alice Krezymon; Alexandre Benani; Luc Pénicaud; Raúl Tudela; Anna Maria Planas; Eduardo Fernández; Maria del Carmen Carmona; Ramon Gomis
Journal:  PLoS One       Date:  2012-07-03       Impact factor: 3.240

4.  GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS.

Authors:  Hagit Eldar-Finkelman; Ana Martinez
Journal:  Front Mol Neurosci       Date:  2011-10-31       Impact factor: 5.639

5.  Tungstate-targeting of BKαβ1 channels tunes ERK phosphorylation and cell proliferation in human vascular smooth muscle.

Authors:  Ana Isabel Fernández-Mariño; Pilar Cidad; Delia Zafra; Laura Nocito; Jorge Domínguez; Aida Oliván-Viguera; Ralf Köhler; José R López-López; María Teresa Pérez-García; Miguel Ángel Valverde; Joan J Guinovart; José M Fernández-Fernández
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

6.  Preclinical and Clinical Studies for Sodium Tungstate: Application in Humans.

Authors:  Romina Bertinat; Francisco Nualart; Xuhang Li; Alejandro J Yáñez; Ramón Gomis
Journal:  J Clin Cell Immunol       Date:  2015-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.